コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ers (eg, rash, pruritus, and urticaria) with insulin glargine.
2 aryngitis reported in 44 (12%) patients with insulin glargine.
3 e, alogliptin, saxagliptin, sitagliptin, and insulin glargine.
4 with 1.0 mg semaglutide, and five (1%) with insulin glargine.
5 1.0 mg semaglutide, and 26 (7%) assigned to insulin glargine.
6 utide, 360 to 1.0 mg semaglutide, and 360 to insulin glargine.
7 degludec than among those who received basal insulin glargine.
8 iated with lower risks of hypoglycaemia than insulin glargine.
9 in the group receiving inhaled insulin plus insulin glargine.
11 Change in HbA(1c) with inhaled insulin plus insulin glargine (-0.68%, SE 0.077, 95% CI -0.83 to -0.5
12 rgine; estimated treatment difference versus insulin glargine -0.38% (95% CI -0.52 to -0.24) with 0.5
13 rgine; estimated treatment difference versus insulin glargine -4.62 kg (95% CI -5.27 to -3.96) with 0
14 lacebo metformin only, placebo metformin and insulin glargine, active metformin only, or active metfo
15 omly assigned to insulin degludec and 157 to insulin glargine; all were analysed in their respective
16 c) level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin
19 nsulin; 107 patients on inhaled insulin plus insulin glargine and 85 on biaspart insulin discontinued
20 ndomized 2 x 2 factorial trial of open-label insulin glargine and placebo-controlled metformin in 500
22 cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85
23 le, double and triple doses of the synthetic insulins glargine and degludec currently used in patient
24 ients were allocated to inhaled insulin plus insulin glargine, and 343 to biaspart insulin; 107 patie
25 efficacy and safety of insulin degludec and insulin glargine, both administered once daily with meal
26 -1 receptor agonist dulaglutide with that of insulin glargine, both combined with prandial insulin li
27 07), respectively, with insulin degludec and insulin glargine (estimated treatment difference -0.01%
28 respectively, versus 0.83% (0.73-0.93) with insulin glargine; estimated treatment difference versus
29 us a weight gain of 1.15 kg (0.70-1.61) with insulin glargine; estimated treatment difference versus
30 comparison with another long-acting insulin, insulin glargine (GLAR), DET led to more prolonged incre
32 Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standar
33 re) were similar in the insulin degludec and insulin glargine groups (42.54 vs 40.18 episodes per pat
35 plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular
36 N-3, exenatide once weekly was compared with insulin glargine (henceforth, glargine) as first injecta
38 and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellit
39 logue in clinical development, compared with insulin glargine in patients with type 2 diabetes who we
40 placebo, or active comparators (glimepiride, insulin glargine, insulin lispro, liraglutide, pioglitaz
42 n glulisine) and basal insulin (for example, insulin glargine or insulin detemir), the analogues simu
44 nosphere inhaled insulin powder plus bedtime insulin glargine; or twice daily premixed biaspart insul
45 with 1.0 mg semaglutide versus 38 (11%) with insulin glargine (p=0.0021 and p=0.0202 for 0.5 mg and 1
49 fixed dose-escalation regimen) or once-daily insulin glargine (starting dose 10 IU per day, then titr
52 e either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between
53 lin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargine U100 (McNemar P = .35; risk difference,
54 eive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin gl
55 eive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin gl
56 nsulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n =
57 nsulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n =
58 patients in the insulin degludec than in the insulin glargine U100 group experienced severe hypoglyce
59 group vs 2462.7 episodes per 100 PYE in the insulin glargine U100 group for a rate ratio (RR) of 0.8
60 c group vs 428.6 episodes per 100 PYE in the insulin glargine U100 group, for an RR of 0.64 (95% CI,
61 h a lower rate of hypoglycemia compared with insulin glargine U100 in patients with type 2 diabetes.
62 sulin degludec is noninferior or superior to insulin glargine U100 in reducing the rate of symptomati
63 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of over
64 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of over
65 tomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 episodes per 1
66 omatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 episodes/100 PYE
67 tomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the full treatm
69 ose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose le
70 tive metformin only, or active metformin and insulin glargine) with dose titration targeting fasting
71 allocation sequence, to insulin degludec or insulin glargine without stratification by use of a cent
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。